ANNOUNCEMENT NO. 318
5 October 2026
Pursuant to section 30 of the Danish Capital Markets Act, notice is hereby given that BlackRock, Inc. has notified ChemoMetec that, on 29 September 2026, BlackRock, Inc. increased its voting rights attached to shares in ChemoMetec to 15.08%, thereby exceeding the 15% threshold under section 38 of the Danish Capital Markets Act.
BlackRock, Inc.’s position at that time was as follows:
- Voting rights attached to shares: 15.08%
- Voting rights through financial instruments: 0.00%
- The total of both: 15.08%
BlackRock, Inc. has previously notified the following:
28 August 2026
BlackRock Investment Management (UK) Limited, which is part of the BlackRock Group, exceeded the 10% threshold under section 38 of the Danish Capital Markets Act and the 10% threshold for its total position under section 40 of the Danish Capital Markets Act.
BlackRock, Inc.’s total position on the same date was as follows:
- Voting rights attached to shares: 12.98%
- Voting rights through financial instruments: 0.05%
- The total of both: 13.03%
At the same time, BlackRock Investment Management (UK) Limited held a total position of 10.04%, comprising 10.04% in voting rights attached to shares and 0.00% through financial instruments.
29 April 2026
BlackRock Investment Management (UK) Limited, which is part of the BlackRock Group, fell below the 10% threshold under section 40 of the Danish Capital Markets Act.
BlackRock, Inc.’s total position on the same date was as follows:
- Voting rights attached to shares: 12.77%
- Voting rights through financial instruments: 0.15%
- The total of both: 12.92%
At the same time, BlackRock Investment Management (UK) Limited held a total position of 9.94%, comprising 9.79% in voting rights attached to shares and 0.15% through financial instruments.
22 April 2026
BlackRock Investment Management (UK) Limited, which is part of the BlackRock Group, fell below the 10% threshold under section 38 of the Danish Capital Markets Act.
BlackRock, Inc.’s total position on the same date was as follows:
- Voting rights attached to shares: 12.94%
- Voting rights through financial instruments: 0.18%
- The total of both: 13.12%
At the same time, BlackRock Investment Management (UK) Limited held a total position of 10.15%, comprising 9.99% in voting rights attached to shares and 0.16% through financial instruments.
Additional Information
Martin Helbo Behrens, CEO
Tel.: (+45) 81 10 06 80
Phillip Massie Price, CFO
Tel.: (+45) 81 10 06 80
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.